Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
Subtype terms (11)
More specific conditions that are subtypes of Neurodegenerative Diseases in the MeSH hierarchy.
- Chronic Traumatic Encephalopathy
8 drugs (4 approved, 4 experimental)
- Heredodegenerative Disorders, Nervous System
4 drugs (2 approved, 2 experimental)
- Motor Neuron Disease
27 drugs (17 approved, 10 experimental)
- Olivary Degeneration
- Paraneoplastic Syndromes, Nervous System
- Postpoliomyelitis Syndrome
8 drugs (6 approved, 2 experimental)
- Prion Diseases
2 drugs experimental
- Subacute Combined Degeneration
- Synucleinopathies
5 drugs (2 approved, 3 experimental)
- Tauopathies
17 drugs (3 approved, 14 experimental)
- TDP-43 Proteinopathies
4 drugs (2 approved, 2 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (7)
Phase 2 trials (24)
- thk-5351
- florbetapir
- lenalidomide
- cobimetinib
- ketorolac
- deferiprone
- levodopa
- peripheral blood lymphocytes
- ropivacaine
- preladenant
- epinephrine
- rotigotine
- Ursodoxicoltaurine
- tocotrienol
- clonidine
- nicotinamide
- sargramostim
- dextromethorphan
- brexanolone
- Cerebral Dopamine Neurotrophic Factor
- xpro1595
- traneurocin
- aoc 1001
- mc2-25
Phase 1 trials (18)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (24)
- Avid Radiopharmaceuticals
- Merck
- Genentech
- Amylyx Pharmaceuticals Inc.
- Herantis Pharma Plc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- Baylor University
- University of London
- Harvard University
- Korea Health Industry Development Institute
- North American Consortium for Histiocytosis
- University of Ulsan
- Karolinska Institute
- University of Genoa
- The Florey Institute of Neuroscience and Mental Health
- ALS Association
- Sungkyunkwan University
- ALS Finding a Cure Foundation
- Northeast ALS Consortium
- Leandro P. Rizzuto Foundation
- China Medical University
- Government of Taiwan
- NeuroActiva
- Renishaw plc.
Organization Involved with Phase 1 Indications (20)
- Corestem, Inc.
- Molecular NeuroImaging
- Parexel
- Voyager Therapeutics
- Affiris AG
- National Institute of Mental Health (NIMH)
- Cornell University
- Hanyang University
- Institut National de la Santé Et de la Recherche Médicale, France
- Institute for Neurodegenerative Disorders
- Medical University Innsbruck
- University of Bordeaux
- Columbia University
- Fujian Medical University
- University of Toulouse
- Forschungszentrum Jülich
- Prosenex Ambulatorium BetriebsgmbH
- Ono Pharmaceuticals
- Hospital Angeles Tijuana
- NKMAX Co., Ltd.
Organization Involved with Other Experimental Indications (10)